Empower Clinics Announces Medical Cannabis Product Distribution Agreement in Oregon

SEATTLE–(BUSINESS WIRE)–Empower Clinics Inc. (CSE: EPW), a leading owner and operator of medical cannabis clinics in the US, today announced that it has signed a distribution agreement with Nova Paths, an innovator in cannabis product development and distribution, to manufacture and sell medical cannabis products to Oregon dispensaries. As part of the agreement, Nova Paths, a licensed wholesaler, will produce and sell medical cannabis products under the Empower product brand, Sollievo.

“This agreement is a strategic step forward for Empower as we continue to leverage our doctors’ research on medical cannabis preparations to ultimately deliver high quality products to patients”

Tweet this

Under terms of the agreement, Nova Paths will make monthly royalty payments to Empower based on product sales.

“This agreement is a strategic step forward for Empower as we continue to leverage our doctors’ research on medical cannabis preparations to ultimately deliver high quality products to patients,” said Craig Snyder, Empower CEO. “Product sales represent a strong market channel for us and we are excited by the opportunity to offer best-in-class products to Oregon’s cannabis consumers. We expect Oregon to be a model for distribution agreements in other medical cannabis markets and the hemp-CBD market as well.”

Today Empower also announced the appointment of Northbay Capital Partners Corp. as strategic financial and M&A advisor to the company. Northbay Capital is a leading Canadian merchant bank with extensive experience in the North American cannabis industry and has been engaged by Empower to help identify, evaluate and structure strategic transactions with an aim to maximize shareholder value.

As part of a planned progression for the company, Empower today also announced the promotion of Carly Krivanek to the position of Chief Financial Officer, effective immediately. Krivanek replaces former CFO Alan Rootenberg, who guided the company’s finances from its early start-up days to now being a publicly traded entity.


Empower is a leading owner and operator of medical cannabis clinics and developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.

For further information about Empower please see the Company’s website at empowerclinics.com or contact the following:

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. Forward-looking information contained in this news release includes, but is not limited to, the delisting of the Common Shares from the TSXV, the listing of the Common Shares on the CSE and the future growth plans of the Company. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events and are therefore based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Neither the TSXV, the CSE nor their Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.


Boom Capital Markets
Steve Low, 647-620-5101
Pointer PR LLC
Mark S. Peterson, 206-390-0204

By |2019-02-01T20:34:03+00:00June 4th, 2018|CBD, Home, Marketing, News, Press|
GDPR Compliance Notice: This site uses cookies and third party tracking scripts to help us improve your website and shopping experience. By continuing to browse our website you are agreeing to our cookie and privacy policies. View Our Privacy Policy Continue